Proteus mirabilis
% Multiresistance per hospital
(resistance to ceftazidime, ciprofloxacin and tobramycin)
All clinical specimens
(January - June 2016)
Hospital | Medical Wards |
Surgical Wards |
ICU |
||||||||
%pmi/total isolates |
Isolates Tested |
%R |
%pmi/total isolates |
Isolates Tested |
%R |
%pmi/total isolates |
Isolates Tested |
%R |
|||
GR001 | 4,5% |
24 |
0,0 |
3,4% |
20 |
0,0 |
3,2% |
12 |
0,0 |
||
GR007 | 5,8% |
6 |
11,7% |
9 |
0,0 |
1,3% |
3 |
||||
GR011* | 2,6% |
16 |
0,0 |
1,0% |
1 |
2,0% |
2 |
||||
GR013 | 4,0% |
9 |
0,0 |
6,0% |
12 |
0,0 |
|||||
GR014 | 4,2% |
28 |
10,7 |
8,3% |
21 |
0,0 |
5,6% |
11 |
27,3 |
||
GR015 | 4,8% |
8 |
0,0 |
5,6% |
2 |
1,0% |
2 |
||||
GR018 | 2,2% |
6 |
4,4% |
5 |
|||||||
GR026 | 3,4% |
14 |
0,0 |
5,7% |
18 |
0,0 |
4,8% |
6 |
|||
GR027 | 4,5% |
17 |
5,9 |
6,3% |
15 |
13,3 |
2,2% |
4 |
|||
GR030 | 3,0% |
24 |
8,3 |
1,8% |
2 |
3,3% |
6 |
||||
GR032 | 9,2% |
46 |
8,7 |
5,8% |
10 |
40,0 |
4,1% |
4 |
|||
GR037 | 7,4% |
42 |
14,3 |
3,0% |
6 |
2,2% |
3 |
||||
GR039 | 5,5% |
29 |
24,1 |
4,3% |
16 |
12,5 |
3,3% |
15 |
40,0 |
||
GR040 | 5,8% |
124 |
30,6 |
4,7% |
40 |
25,0 |
3,2% |
18 |
55,6 |
||
GR041 | 4,1% |
44 |
20,5 |
5,3% |
24 |
8,3 |
4,4% |
10 |
20,0 |
||
GR042 | 7,1% |
21 |
0,0 |
6,1% |
5 |
||||||
GR043 | 5,1% |
49 |
2,0 |
1,6% |
1 |
2,6% |
4 |
||||
GR047 | 5,7% |
63 |
4,8 |
5,1% |
34 |
2,9 |
3,4% |
4 |
|||
GR048 | 9,8% |
12 |
33,3 |
3,5% |
6 |
20,0% |
8 |
25,0 |
|||
GR049 | 10,2% |
30 |
13,3 |
7,0% |
9 |
0,0 |
7,3% |
9 |
0,0 |
||
GR051 | 8,5% |
28 |
7,1 |
2,5% |
4 |
8,8% |
8 |
0,0 |
|||
GR055 | 2,2% |
4 |
2,0% |
2 |
|||||||
GR057* | 5,8% |
1 |
|||||||||
GR062 | 5,5% |
52 |
15,4 |
6,2% |
20 |
10,0 |
|||||
GR068 | 8,0% |
17 |
0,0 |
4,2% |
35 |
11,4 |
1,3% |
2 |
|||
GR077 | 12,7% |
20 |
20,0 |
6,9% |
12 |
25,0 |
5,5% |
6 |
|||
Weighted Average | 5,3% |
734 |
13,2 |
5,0% |
329 |
10,0 |
3,2% |
137 |
22,6 |
||
Hospital Mean | 10,0 |
9,9 |
21,0 |